Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,772.00GBp
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
4,772.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,282,928
52-wk High
5,585.07
52-wk Low
4,260.00

Select another date:

Wed, Feb 21 2018

Photo

U.S. health officials reverse stance on AstraZeneca's flu vaccine

AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

U.S. health officials reverse stance on AstraZeneca's flu vaccine

AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

U.S. health officials reverse stance on AstraZeneca's flu vaccine

Feb 21 AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

BRIEF-Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine

* ASTRAZENECA ANNOUNCES RENEWED RECOMMENDATION AND AVAILABILITY OF FLUMIST QUADRIVALENT VACCINE IN THE US

BRIEF-Ionis Licences New Antisense Drug For Kidney Disease To Astrazeneca

* IONIS LICENCES NEW ANTISENSE DRUG FOR KIDNEY DISEASE TO ASTRAZENECA

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

UPDATE 2-AstraZeneca's immunotherapy drug wins key lung cancer approval

* Rival BMS, Merck, Roche drugs approved for later disease (Adds shares, analyst reaction)

BRIEF-AstraZeneca ‍Says US FDA Approves Imfinzi For Unresectable Stage III Non-Small Cell Lung Cancer​

* ‍US FDA APPROVES IMFINZI FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER​

U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's , immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumours can't be surgically removed.

Select another date: